The nurse will plan to teach a patient with Crohn's disease who has megaloblastic anemia about the need for:

Choice A reason: Crohn's disease frequently involves the terminal ileum, the specific anatomical site responsible for the absorption of the vitamin B12-intrinsic factor complex. When the ileum is inflamed or resected, B12 cannot be absorbed enterally, leading to megaloblastic anemia, necessitating parenteral or intranasal cobalamin replacement therapy. Choice B reason: Iron dextran is an intravenous iron replacement used for iron deficiency anemia when oral intake is ineffective or contraindicated. Megaloblastic anemia in Crohn's disease is typically characterized by macrocytic changes due to B12 or folate deficiency, rather than microcytic changes associated with depleted iron stores. Choice C reason: Oral ferrous sulfate is used to treat iron deficiency anemia. In patients with active Crohn's disease, oral iron is often poorly tolerated due to gastrointestinal irritation and may be poorly absorbed if there is extensive intestinal involvement. Furthermore, it does not address the underlying B12 deficiency. Choice D reason: Blood transfusions are reserved for severe, life-threatening anemia or acute hemorrhage. Megaloblastic anemia is a chronic nutritional deficiency that is more appropriately and safely managed through specific vitamin replacement therapy (B12 or folic acid) rather than the risks associated with repeated allogeneic blood product administration.